A pilot study using nabilone for symptomatic treatment in Huntington's disease

Movement Disorders

Volumn 24, Issue 15, 2009, Pages 2254-2259

  Curtis, Adrienne ^a,c   Mitchell, Ian ^b   Patel, Smitaa ^b   Ives, Natalie ^b   Rickards, Hugh ^a  

^a BIRMINGHAM AND SOLIHULL MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c Robert Aitken Institute ^*  (United Kingdom)

Author keywords

Cannabinoids; Chorea; Huntington's disease; Nabilone; Psychiatric symptoms

Indexed keywords

NABILONE; PLACEBO; TEMAZEPAM;

ADULT; AGED; AMNESIA; ARTICLE; ASTHMA; BEHAVIOR; CHOREA; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EUPHORIA; EVENING DOSAGE; FEASIBILITY STUDY; FEMALE; HEART PALPITATION; HUMAN; HUNTINGTON CHOREA; MALE; MORNING DOSAGE; NEUROPSYCHIATRY; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEDATION; SEIZURE; SIDE EFFECT; SUICIDAL IDEATION; SYMPTOMATOLOGY;

ADULT; AGED; ANTI-ANXIETY AGENTS; BEHAVIORAL SYMPTOMS; COGNITION DISORDERS; CROSS-OVER STUDIES; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OUTCOME ASSESSMENT (HEALTH CARE); PILOT PROJECTS; TETRAHYDROCANNABINOL;

EID: 72849149551     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22809     Document Type: Article

References (14)

1. Paulsen JS, Ready RE, Hamilton JM, Mega MS, Cummings JL. Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry 2001;71:310-314.
2. Bonelli RM, Hofmann P. A systematic review of the treatment studies in Huntington's disease since 1990. Exp Opin Pharmacother 2007;8:141-153.
3. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997;74:129-180.
4. Moore TH, Zammit S, Lingford HA, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007;370:319-328. (Pubitemid 47094993)
5. Zajicek J. The cannabinoids in MS study-final results from 12 month follow up. Multiple Sclerosis 2004;10(suppl):s115.
6. Müller V, Kirsten R. The treatment of Tourette's syndrome: current opinions. Exp Opin Pharmacother 2002;3:899-914. (Pubitemid 34752508)
7. Croxford JL. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 2003;17:179-202. (Pubitemid 36286534)
8. Curtis A, Rickards H. Nabilone could treat chorea and irritability in Huntington's disease. J Neuropsychiatry Clin Neurosci 2006;18:553-554. (Pubitemid 44713898)
9. Muller VKR, Schneider U, Emrich HM. Nabilone increases choreatic movements in Huntington's disease. Mov Disord 1999;14:1038-1040.
10. Kieburtz K, Penney JB, Como P, et al. Unified Huntington's disease rating scale: reliability and consistency. Mov Disord 1996;11:136-142. (Pubitemid 26082779)
11. Cummings JL, Mega M, Gray K, Rosenberg TS, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314. (Pubitemid 24382728)
12. Jones B, Kenward MG, editors. Design and analysis of cross-over trial. London: Chapman and Hall/CRC; 1998.
13. Senn S. Cross-over trials in clinical research. Chichester: Wiley; 2002.
14. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005;76:1664-1669.